Biodesix Q2 Revenue Jumps 34%, Beats Estimates; Margins Expand
BDSX has more than doubled off its 52-week low of $5.26.
Summary
Biodesix delivered a strong Q2 with revenue of $26.86M, up 34% YoY and ahead of the $26.03M consensus. Gross margin expanded 200 bps to 82%, driven by a 38% jump in test volumes and higher average revenue per test. Net loss narrowed 37% to $7.3M, showing operating leverage. The company reaffirmed FY2026 revenue guidance of $108-114M, implying ~25% growth at the midpoint, and expects to sustain ~80% gross margins. This follows the Q1 report that highlighted revenue growth and reduced losses, and the recent S-3 filing for a lender's resale of shares. The beat and margin expansion signal accelerating commercial traction in lung cancer diagnostics.
At the time of this announcement, BDSX was trading at $22.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $235.9M. The 52-week trading range was $5.26 to $24.92. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.